Literature DB >> 33130331

Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia.

Tugcan Alp Kirkizlar1, Halis Akalin2, Onur Kirkizlar3, Fahir Ozkalemkas4, Vildan Ozkocaman5, Esra Kazak6, Cuneyt Ozakin7, Esra Nur Bulbul8, Ezgi Sezen Ozboz9, Rıdvan Ali10.   

Abstract

BACKGROUND: Vancomycin-resistant enterococcus (VRE) is an infectious agent that can increase morbidity and mortality, especially in patients with neutropenia in haematology departments. We analysed VRE infections and mortality rates among VRE colonized patients with acute leukaemia, defined predisposing risk factors for infection and mortality, and investigated the influence of daptomycin or linezolid treatment on mortality. PATIENTS-
METHODS: We included 200 VRE colonized adult acute leukaemia patients with febrile neutropenia between January 2010 and January 2016. Data were collected from electronic files.
RESULTS: There were 179 patients in the colonized group, and 21 patients in the infected group. Enterococcus faecium (van A) was isolated from all patients. The infection rate was 10.5 %, and the types of infections noted were as follows: bloodstream (n = 14; 66.7 %), skin and soft tissue (n = 3; 14.3 %), urinary (n = 2; 9.5 %), and others (9.5 %). In the multivariate logistic regression analysis, exposure to invasive procedures, coinfection status, and >15 days of VRE positivity were independent risk factors for VRE infections. In hospital mortality rates were 57.1 % in the infected group, and 9.5 % in the colonized group (p < 0.001). Older age, female gender, absolute neutropenia, and coinfection status were statistically significant predictor of survival.
CONCLUSION: Vancomycin-resistant enterococcus infections are associated with high morbidity and mortality in haematology patients with neutropenia. Clinicians should be aware of predisposing risk factors for VRE infection to avoid unfavourable outcomes. We believe that larger studies are necessary regarding the influence of treatment with daptomycin and linezolid.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute leukaemia; Daptomycin; Linezolid; Risk factors; Vancomycin-resistant enterococcus; febrile neutropenia

Mesh:

Substances:

Year:  2020        PMID: 33130331     DOI: 10.1016/j.leukres.2020.106463

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Evaluation of Using Empiric Glycopeptides in Accordance with the IDSA Guidelines in Hematologic Malignancy Patients with Febrile Neutropenia.

Authors:  Cumali Yalçın; Fahir Özkalemkaş; Vildan Özkocaman; Tuba Ersal; İbrahim Ethem Pınar; Bedrettin Orhan; Ömer Candar; Sinem Çubukçu; Tuba Güllü Koca; Merve Nur Akyol; Nevriye Gül Ada; Cüneyt Özakın; Esra Kazak; Halis Akalın; Rıdvan Ali
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-05-01       Impact factor: 3.122

Review 2.  Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences.

Authors:  Dean G Campelj; Cara A Timpani; Emma Rybalka
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-12-08       Impact factor: 12.910

3.  Two Novel Lytic Bacteriophages Infecting Enterococcus spp. Are Promising Candidates for Targeted Antibacterial Therapy.

Authors:  Pavel V Tkachev; Ivan M Pchelin; Daniil V Azarov; Andrey N Gorshkov; Olga V Shamova; Alexander V Dmitriev; Artemiy E Goncharov
Journal:  Viruses       Date:  2022-04-16       Impact factor: 5.818

4.  Prevalence of Vancomycin-Resistant Enterococci and Antimicrobial Residues in Wastewater and Surface Water.

Authors:  Kristýna Hricová; Magdaléna Röderová; Petr Fryčák; Volodymyr Pauk; Ondřej Kurka; Kristýna Mezerová; Taťána Štosová; Jan Bardoň; David Milde; Pavla Kučová; Milan Kolář
Journal:  Life (Basel)       Date:  2021-12-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.